| Website | regimmune.com |
| Category | BioTech |
| Employees | |
| Founded | 3/06 |
| TOTAL | $11.8M |
| VENTURE FUNDING TOTAL | $11.8M |
| Seed, 8/06 NIF SMBC Ventures Nikko Antfactory Japan Asia Investment | $1.6M |
| Series A, 2/07 NIF SMBC Ventures Japan Asia Investment Jafco Ventures Orix Capital Corporation Yasuda Enterprise Development New Business Investment Mitsubishi UFJ Capital Fund Creation | $4.2M |
| Series B, 2/08 NIF SMBC Ventures CSK Venture Capital Resona Capital AC Ventures Friendly Partners Japan Asia Investment Yasuda Enterprise Development New Business Investment Fund Creation | $6M |
REGiMMUNE Corporation is a biotechnology company focused on the discovery, development, and potential commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders, including allergies, autoimmune and inflammatory disease. REGiMMUNE applies its reVax (reverse vaccination) technology and product development and clinical experience to generate, support and potentially commercialize a broad range of products for itself and its partners.
